Key facts: NASDAQ:GPCR Aleniglipron 16.2% Loss; CEO: Safety, Lower Costs

Structure Therapeutics (GPCR) reported a 3.3% weight-loss signal in a Phase 1/2a trial of ACCG-2671. The study involved 31 healthy adults, with six participants receiving 10mg showing the mean reduction. The company is now testing daily and weekly regimens in an 84-day study, with results expected in 2027. Investors focus on sustained efficacy and tolerability, as gastrointestinal side effects were reported at higher doses.

Structure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence o

Structure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial

Polymarket traders and analysts are focusing on Viking Therapeutics (VKTX) as an obesity M&A target, citing an estimated 38.5% implied acquisition probability before 2027. The company has no revenue and a ~$3.59B market cap; shares closed at $30.89 on May 22, 2026. Analysts’ mean target is $92.33. Viking’s oral VK2735 showed up to 12.2% weight loss at 13 weeks, and Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Potential buyers mentioned include Eli Lilly, Pfizer, and Novo Nordisk.

Merck (MRK) and Moderna (MRNA) reported Phase 3 trial results showing their personalized mRNA cancer vaccine, intismeran, combined with KEYTRUDA, reduced melanoma recurrence risk by 42% vs. KEYTRUDA alone. The two-year recurrence-free survival rate was 82.2% for the combination vs. 70.0% for KEYTRUDA. The companies plan to discuss results with regulators and advance further studies. MRK stock closed at $147.24, down 1.76%.

Moderna and Merck's personalized cancer vaccine, intismeran autogene, reduced melanoma recurrence or death risk by 42% and spread risk by 38% in a Phase 3 trial. The vaccine, combined with Merck's Keytruda, showed 82.2% cancer-free rate after two years. The companies plan to seek regulatory approval.